Evidence map›Paper›PMID 39910273›Full record

Trial reportNature medicine2025

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner, Marc Braunstein, Ludek Pour, Josep M Martí, Supratik Basu, Yael C Cohen and 21 more

Erratum issuedAbstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 95 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

Saad Z UsmaniMemorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org.ORCID http://orcid.org/0000-0002-5484-8731
Thierry FaconUniversity of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France.
Vania HungriaClínica Médica São Germano, São Paulo, Brazil.
Nizar J BahlisArnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.ORCID http://orcid.org/0000-0001-7353-7034
Christopher P VennerDepartment of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
Marc BraunsteinPerlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Ludek PourUniversity Hospital Brno, Brno, Czech Republic.
Josep M MartíHospital Universitario Mútua de Terrassa, Terrassa, Spain.
Supratik BasuRoyal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK.ORCID http://orcid.org/0000-0003-2206-4796
Yael C CohenDepartment of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel.ORCID http://orcid.org/0000-0002-9061-7287
Morio MatsumotoDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Cyrille HulinDepartment of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
Sebastian GrosickiDepartment of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland.
Wojciech LegiecDepartment of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland.
Meral BeksacIstinye University, Ankara Liv Hospital, Ankara, Turkey.
Angelo MaiolinoInstituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0003-0140-9548
Hiroyuki TakamatsuDepartment of Hematology, Kanazawa University Hospital, Kanazawa University, Kanazawa, Japan.
Aurore PerrotCHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.ORCID http://orcid.org/0000-0003-0131-8689
Mehmet TurgutDepartment of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey.
Tahamtan AhmadiGenmab US, Inc., Plainsboro, NJ, USA.
Weiping LiuJohnson & Johnson, Shanghai, China.
Jianping WangJohnson & Johnson, Spring House, PA, USA.
Katherine ChastainJohnson & Johnson, Raritan, NJ, USA.
Jessica VermeulenJohnson & Johnson, Leiden, The Netherlands.
Maria KrevvataJohnson & Johnson, Spring House, PA, USA.
Lorena Lopez-MasiJohnson & Johnson, Raritan, NJ, USA.
Jodi CareyJohnson & Johnson, Spring House, PA, USA.
Melissa RoweJohnson & Johnson, High Wycombe, UK.
Robin CarsonJohnson & Johnson, Spring House, PA, USA.
Sonja ZweegmanDepartment of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Frontline daratumumab-based triplet and quadruplet standard-of-care regimens have demonstrated improved survival outcomes in newly diagnosed multiple myeloma (NDMM). For patients with transplant-ineligible NDMM, triplet therapy with either daratumumab plus lenalidomide and dexamethasone (D-Rd) or bortezomib, lenalidomide and dexamethasone (VRd) is the current standard of care. This phase 3 trial evaluated subcutaneous daratumumab plus VRd (D-VRd) in patients with transplant-ineligible NDMM or for whom transplant was not planned as the initial therapy (transplant deferred). Some 395 patients with transplant-ineligible or transplant-deferred NDMM were randomly assigned to eight cycles of D-VRd or VRd followed by D-Rd or Rd until progression. The primary endpoint was overall minimal residual disease (MRD)-negativity rate at 10

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneLenalidomideMultiple MyelomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm, ResidualProgression-Free SurvivalAntibodies, MonoclonalBortezomibdaratumumabDexamethasoneLenalidomide

Identifiers

PMID39910273
PMCPMC12003169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.